The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Mark Gilbert named chief of Neuro-Oncology Branch at NIH

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MARK GILBERT was named chief of the Neuro-Oncology Branch at the NIH, within the Center for Cancer Research of NCI.

Gilbert was previously deputy chairman of the Department of Neuro-Oncology at MD Anderson Cancer Center.

The Neuro-Oncology Branch is a cooperative program between the NCI and the National Institute for Neurological Disorders and Stroke. Established in 2000, the NOB became one of the first trans-institutional initiatives at the NIH.

Gilbert has served as co-chair of the Brain Tumor Committee for the Radiation Therapy Oncology Group since 2010, and has been the primary investigator on a number of pivotal studies in the field of neuro-oncology. He is expected to begin his new role in late November.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.
By Claire Marie Porter
Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several  aggressive cuts the White House had proposed for NIH.
By Jacquelyn Cobb
Guest Editorial

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer. 
By E. Anders Kolb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account